Literature DB >> 20036004

Ezrin is a key molecule in the metastasis of MOLT4 cells induced by CCL25/CCR9.

Beibei Zhou1, Jun Leng, Meng Hu, Li Zhang, Zhan Wang, Dongying Liu, Xiaoling Tong, Beibei Yu, Yi Hu, Chaohua Deng, Yanping Liu, Qiuping Zhang.   

Abstract

Chemokines and their corresponding receptors participate in transmigration of leukemic cells. ERM (ezrin/radixin/moesin) protein family act as linkers between the plasma membrane and the cytoskeleton and are key component in tumor metastasis. In this study we used the CCR9-expressing acute T lymphocytic cell line MOLT4 as a model and assesssed their morphological and functional changes in response to CCL25. The pseudopodium formed and ERM translocated from the cytoplasm to the cell membrane following treatment with CCL25. Ezrin silencing by miRNA showed that ezrin plays important roles in the polarization and invasive behaviour of MOLT4 cells. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20036004     DOI: 10.1016/j.leukres.2009.11.025

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  12 in total

1.  NHE1 has a notable role in metastasis and drug resistance of T-cell acute lymphoblastic leukemia.

Authors:  Ehtisham Altaf; Xiaoxing Huang; Jie Xiong; Xiangyong Yang; Xinzhou Deng; Meng Xiong; Lu Zhou; Shan Pan; Wen Yuan; Xinran Li; Ling Hao; Kingsley Miyanda Tembo; Ruijing Xiao; Qiuping Zhang
Journal:  Oncol Lett       Date:  2017-08-03       Impact factor: 2.967

2.  CCL25 Signaling in the Tumor Microenvironment.

Authors:  Hina Mir; Shailesh Singh
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 3.  CCR9 in cancer: oncogenic role and therapeutic targeting.

Authors:  Zhenbo Tu; Ruijing Xiao; Jie Xiong; Kingsley M Tembo; Xinzhou Deng; Meng Xiong; Pan Liu; Meng Wang; Qiuping Zhang
Journal:  J Hematol Oncol       Date:  2016-02-16       Impact factor: 17.388

4.  Wnt5a and CCL25 promote adult T-cell acute lymphoblastic leukemia cell migration, invasion and metastasis.

Authors:  Xinzhou Deng; Zhenbo Tu; Meng Xiong; Kingsley Tembo; Lu Zhou; Pan Liu; Shan Pan; Jie Xiong; Xiangyong Yang; Jun Leng; Qian Zhang; Ruijing Xiao; Qiuping Zhang
Journal:  Oncotarget       Date:  2017-06-13

5.  The interaction of lncRNA EZR-AS1 with SMYD3 maintains overexpression of EZR in ESCC cells.

Authors:  Xiao-Dan Zhang; Guo-Wei Huang; Ying-Hua Xie; Jian-Zhong He; Jin-Cheng Guo; Xiu-E Xu; Lian-Di Liao; Yang-Min Xie; Yong-Mei Song; En-Min Li; Li-Yan Xu
Journal:  Nucleic Acids Res       Date:  2018-02-28       Impact factor: 16.971

6.  Comprehensive analysis of cytoskeleton regulatory genes identifies ezrin as a prognostic marker and molecular target in acute myeloid leukemia.

Authors:  Jean Carlos Lipreri da Silva; Juan Luiz Coelho-Silva; Keli Lima; Hugo Passos Vicari; Mariana Lazarini; Leticia Veras Costa-Lotufo; Fabiola Traina; João Agostinho Machado-Neto
Journal:  Cell Oncol (Dordr)       Date:  2021-07-01       Impact factor: 6.730

7.  Activated ERM protein plays a critical role in drug resistance of MOLT4 cells induced by CCL25.

Authors:  Li Zhang; Ruijing Xiao; Jie Xiong; Jun Leng; Altaf Ehtisham; Yi Hu; Qianshan Ding; Hui Xu; Shengwu Liu; Jin Wang; Dean G Tang; Qiuping Zhang
Journal:  PLoS One       Date:  2013-01-09       Impact factor: 3.240

8.  miR-96 suppresses renal cell carcinoma invasion via downregulation of Ezrin expression.

Authors:  Nengwang Yu; Shuai Fu; Yubao Liu; Zhonghua Xu; Yi Liu; Junwen Hao; Baocheng Wang; Aimin Zhang
Journal:  J Exp Clin Cancer Res       Date:  2015-09-29

Review 9.  The role of chemokine receptor 9/chemokine ligand 25 signaling: From immune cells to cancer cells.

Authors:  Cong Wang; Zhenghuan Liu; Zhihui Xu; Xian Wu; Dongyang Zhang; Ziqi Zhang; Jianqin Wei
Journal:  Oncol Lett       Date:  2018-06-04       Impact factor: 2.967

10.  Knockdown of Ezrin inhibited migration and invasion of cervical cancer cells in vitro.

Authors:  Meili Xi; Wenbin Tang
Journal:  Int J Immunopathol Pharmacol       Date:  2020 Jan-Dec       Impact factor: 3.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.